7210 Wareham Drive, Tampa, FL 33647
March 4, 2026 Marketdata LLC has released a new report: “The U.S. Weight Loss Market: Status Report & 2026 Forecast” This 108-page analysis tracks the current status of ALL weight loss market segments, 2025 performance, the latest dieting trends, 15 competitor profiles, with 27 tables and charts. Some findings: The total U.S. weight loss market […]
U.S. Weight Loss Market Now Worth $135 Billion – New Report Read More »
Nov. 4, 2025 Management reported the foillowing: Revenue: $89.4 million, with revenue per active earning coach of $4,585 Active Coaches: Independent active earning OPTA VIA ® coaches of 19,500 Net Loss: $2.3 million or $0.21 loss per diluted share Strong Balance Sheet: $173.5 million in cash, cash equivalents, and investment securities with no debt “We’re transforming Medifast from a
Medifast Reports Q3 Results – Slide Continues Read More »
Sept. 9, 2025 According to Reuters, “The U.S. Food and Drug Administration is tightening oversight of imports of GLP-1 drug ingredients, used for weight loss and diabetes, amid concerns that many of the items may be adulterated and pose a safety risk. The move comes as the FDA cracks down on unapproved compounded drugs, which
FDA Tightens Oversight of GLP-1 Ingredients Imports Read More »
August 11, 2025 The company emerged from its financial reorganization process on June 24, 2025. According to Tara Comonte, CEO of Weight Watchers: “This marks the beginning of an exciting new chapter for the Company, one that’s grounded in stronger financial footing and a clear sense of opportunity. With greater flexibility to invest, we’re accelerating
Weight Watchers Reports Q2 2025 Results Read More »
July 2, 2025 Weight Watchers announced an expanded collaboration with Novo Nordisk, which includes increased access to authentic, FDA-approved Wegovy® (semaglutide) injection through Weight Watchers Clinic. As part of the collaboration, Weight Watchers Clinic members will benefit from a simplified prescription process via NovoCare® Pharmacy. CenterWell Pharmacy®, which serves as the dispensing pharmacy for the
Weight Watchers Expands Collaboration With Novo Nordisk Read More »
April 24, 2025 The U.S. Census of Service Industries is performed every 5 years, with the last government survey performed in 2022. Commercial weight loss companies (“diet & reducing centers”) are classified under NAICS code 812191 (other personal services). Establishment and firms data for this industry have just been released (see census.gov). This information is
2022 Census Data Published: Commercial Weight Loss Industry Statistics Read More »
April 24, 2025 Novo Nordisk asked the Food and Drug Administration to approve a pill version of its popular weight loss drug in obesity earlier this year, a spokesperson confirmed. The company first reported in 2023 that the drug, an oral form of semaglutide, succeeded in a Phase 3 trial, helping people on the highest
Novo Nordisk Submits Weight Loss Pill for FDA Approval Read More »
April 22, 2025 Marketdata LLC has just released a new market study: “The U.S. Meal Replacements Market: Retail & MLM Channels”, April 2025. This 77-page report analyses the meal replacements and retail appetite suppressants market in the U.S. The $5.1 billion U.S. meal replacements market has held up fairly well the past few years, despite
$5 Billion U.S. Meal Replacements Market Survives GLP-1s Competition Read More »
April 2, 2025 Robard, the medical weight loss company, has begun selling its shakes, puddings, soups and beverages direct to the public via a new website. These products are part of its New Direction program. This is a departure from its long-standing policy where you had to sign up for the program to get access
Robard Begins Selling Diet Foods Direct to Consumers Read More »
March 24, 2025 Marketdata LLC has just published a new report: “The U.S. Weight Loss Market: Commercial (non-medical) Programs & Products”, March 2025. This is a 220-page analysis of commercial weight loss programs/companies and how they have been affected by and respond to the onslaught of the GLP-1 drugs competition. The $38 billion U.S. commercial weight loss
$38.4 Billion U.S. Commercial Weight Loss Market Pivots To Survive GLP-1 Drugs Explosion Read More »